Denali Therapeutics Inc. DNLI Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s proceeds from exercises of stock options and other stock issuances?
- Denali Therapeutics Inc. (DNLI) reported proceeds from exercises of stock options and other stock issuances of $6.7M in Q1 2026.
- How has Denali Therapeutics Inc.'s proceeds from exercises of stock options and other stock issuances changed year-over-year?
- Denali Therapeutics Inc.'s proceeds from exercises of stock options and other stock issuances increased by 1025.2% year-over-year, from $595K to $6.7M.
- What is the long-term trend for Denali Therapeutics Inc.'s proceeds from exercises of stock options and other stock issuances?
- Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s proceeds from exercises of stock options and other stock issuances has grown at a -18.7% compound annual growth rate (CAGR), from $19.35M to $8.46M.